NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has been appointed to the Biotechnology Industry Organization’s (BIO’s) Board of Directors as a member of the Health Section Governing Board. BIO is the world’s largest biotechnology trade association. It represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. Dr. Nader brings more than three decades of global experience and expertise as both an industry leader and a physician to BIO’s Health Section Governing Board. “It’s a pleasure to serve on the BIO board alongside many of the biotechnology industry’s leading executives,” said Dr. Nader. “I share BIO’s commitment to promoting biomedical innovation and finding ways to reduce hurdles to life-saving therapies.” “Francois Nader is highly respected within the industry and we are thrilled he is joining BIO’s Board of Directors to share his expertise and insights on how to propel this industry forward through policy and advocacy efforts and business development support for companies both large and small. We welcome Dr. Nader and look forward to his participation on the Board,” said Jim Greenwood, President and CEO, BIO. About NPS Pharmaceuticals NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (ex-U.S.) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of adult hypoparathyroidism and expects to submit its marketing application to the U.S. Food and Drug Administration in the fourth quarter of 2013. NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin.
“NPS,” “NPS Pharmaceuticals,” “Gattex,” “Natpara,” “Preotact,” and “Revestive” are the company's trademarks.